NCT04971226 2026-04-06A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNovartisPhase 3 Active not recruiting405 enrolled 18 charts 3 FDA
NCT04948333 2026-03-18Asciminib Treatment Optimization in ≥ 3rd Line CML-CPNovartisPhase 3 Completed199 enrolled 13 charts